September 13, 2022
Research Report
Independent analysis
Report ID: 25205

noble

Onconova Therapeutics Inc. (ONTX) - Rigosertib Phase 1/2a Trial Data Reported At ESMO


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
0 min read
Get a Report
Refer to the full report for the price target, fundamental analysis, and rating.

The Company in this report is a participant in the Company Sponsored Research Program (“CSRP”); Noble receives compensation from the Company for such participation. No part of the CSRP compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report. The Company has attended Noble investor conference(s) in the last 12 months. Noble has arranged non-deal roadshow(s) with investors in the last 12 months.

Noble has managed or co-managed a public offering in the past 12 months. Noble has received compensation for investment banking services in the past 12 months.

Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) within the next 3 months.


Onconova Therapeutics Inc.
Onconova Therapeutics Inc.
Healthcare
Biotechnology
Ticker
ONTX
Current Price
$0.948 -1.94%
Market Cap
$19.8M
Price Target
Refer to Report
Volume
94.5K
52wk Range
$0.93 - $5.6
Related Research Reports
9/13/2022

Rigosertib Phase 1/2a Trial Data Reported At ESMO
Rigosertib Phase 1/2a Trial Data Reported At ESMO (ONTX)
8/12/2022

All Trials Continue Toward Data Milestones
All Trials Continue Toward Data Milestones (ONTX)
5/12/2022

Clinical Trials Progressing As Expected As 1Q22 Reported
Clinical Trials Progressing As Expected As 1Q22 Reported (ONTX)
4/4/2022

Narazaciclib Data Presented At Scientific Industry Conference
Narazaciclib Data Presented At Scientific Industry Conference (ONTX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.